Adherence to antihypertensive treatment was associated with a reduced risk of death among elderly patients, including frail individuals, according to a large study published in Hypertension.
According to a new analysis of the AMBER study, more heart failure patients treated with patiromer than placebo remained on spironolactone therapy at 12 weeks.
Mortality similar with renin-angiotensin-aldosterone system inhibitor, non-RAAS inhibitor for hypertension.
Journals issue ‘expressions of concern’ over two recent studies of medications and their effect on COVID-19 patients.
Lowering systolic BP to <120 mm Hg lowers risk by 26%.
Larger thighs tied to lower risk for hypertension in overweight, obese Chinese population.
Use of ACE inhibitors, ARBs not tied to higher plasma ACE2 concentrations in those with heart failure.
No significant association identified in overlap propensity score weighting analysis.
Three studies published in the New England Journal of Medicine on May found no evidence that the use of ACE inhibitors or angiotensin-receptor blockers increase the likelihood of SARS-CoV-2 infection or worsen COVID-19 disease course.
These adults may be at increased risk due to existing chronic conditions including CVD, diabetes, HTN.
